Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Alexion Pharma

Bristol-Myers

CVS Health

Jazz Pharmaceuticals

The coronavirus crash has pushed forward price-to-earnings ratios for these healthcare companies down to between 3 and 7.

5 Healthcare Stocks That Haven't Been This Cheap in at Least 10 Years

Apple

Mastercard

These three Warren Buffett stocks appear to be dirt cheap. But are they buys?

Should You Invest in These 3 Buffett Stocks at Discount Prices?

Small trials in China have raised hopes that chloroquine and hydroxychloroquine might be effective against the novel coronavirus, but the data from those studies is sparse and murky.

New York to Start Clinical Trials of Anti-Malaria Drugs for COVID-19

Biogen

Johnson & Johnson

Biogen, Johnson & Johnson, and Teva Pharmaceutical Industries are all way too cheap right now.

Are These Warren Buffett Stocks a Buy at Beaten-Down Prices?

Amneal Pharmaceuticals

Bayer AG

Mylan

Novartis

No, but doctors can still use the drugs despite limited evidence of their effectiveness.

Are Chloroquine and Hydrochloroquine Approved to Treat COVID-19?

Preliminary studies done in China suggest the decades-old malaria drug could inhibit the growth of the novel coronavirus.

Teva Donating More Than 10 Million Doses of Hydroxychloroquine as Potential COVID-19 Treatment

Teva Pharmaceutical Industries (NYSE: TEVA) shares were trading higher on Friday.

Why Teva's Stock Is Trading Higher Today

Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.

Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus

Shares of Teva Pharmaceutical Industries Ltd. TEVA, +7.17% gained 13% in premarket trading on Friday following a Thursday night announcement that the drugmaker will donate more than 6 million doses of hydroxychloroquine sulfate tablets in the U.S.

Teva to donate 6 million doses of hydroxychloroquine, floated as a potential treatment for COVID-19

Teva Pharmaceuticals Near 20-Year Lows

American Eagle Outfitters

U.S. Bancorp

Patient investors in these companies should be handsomely rewarded.

3 Stocks That Will Make You Richer If You Buy During This Correction

Healthcare experts are warning hospital operators that the coronavirus epidemic could lead to shortages of a range of medical supplies.

COVID-19 Outbreak Threatens U.S. Hospitals' Supply Chains

Duke Energy

Kroger

Procter & Gamble

Hostess Brands

Waste Management

Walmart

As the coronavirus pandemic worsens, stable but boring recession-proof stocks to buy are suddenly in vogue. Here are the nine picks that might ride this black swan even to profitability.

9 Recession-Proof Stocks to Disinfect the Coronavirus

Amazon

Delta Air Lines

These Warren Buffett stocks are potentially more attractive than they've ever been.

3 Buffett Stocks That Are Historically Cheap

The long-beleaguered drugmaker may finally be positioned for growth again.

Why Teva Gained Nearly 11% in February

Masimo

Merit Medical Systems

Welltower

With a world that is very concerned over the spread of the coronavirus, health care stocks, especially the top pharmaceutical stocks, have been in the spotlight as researchers scurry to find a cure.

Raymond James Makes Huge Changes To Healthcare Top Picks List

AstraZeneca

Merck

The FDA says that China's COVID-19 containment efforts have led one pharmaceutical company to warn of a looming supply-chain problem.

Coronavirus Disruptions in China Beginning to Affect U.S. Drug Supplies

TEVA stock was a great contrarian play last fall. With opioid liabilities hanging like an anvil over the company, shares were priced for disaster.

Teva Stock Was a Good Buy Last Fall, but It Topped out After This Rally

A Relative Strength Rating upgrade for Teva Pharmaceutical shows improving technical performance.
The post Stocks To Watch: Teva Pharmaceutical Sees Relative Strength Rating Rise To 94 appeared first on Investor's Business Daily.

Stocks To Watch: Teva Pharmaceutical Sees Relative Strength Rating Rise To 94

TEVA stock has rallied as its business has stabilized. But even with shares still cheap, investors shouldn't ignore the myriad risks.

Potholes Remain for Teva Pharmaceutical Stock

The forward price-earnings ratio of Teva stock is only five, and its trailing price/sales ratio is 0.8. With Teva's financial situation in control and given the company's multiple growth drivers, those valuation metrics are quite low.

Now That Teva Has Stabilized, Teva Stock Looks Undervalued

A generic approval for Perrigo of Teva's ProAir HFA was highly anticipated.

Teva Pharmaceutical Gets a Taste of Its Own Medicine As the FDA Approves a Generic of Its Asthma Drug

Berkshire Hathaway's two pure-play pharmaceutical investments are far risker than its other holdings.

Warren Buffett's Two Pure Play Pharma Picks Are Real Head-Scratchers

Pfizer

The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.

3 Best Drugmakers That Are Immune to Coronavirus Fright

It's a disappointing setback for a drug that has received previous approvals for similar conditions.

Teva Pharmaceutical's Tourette Syndrome Drug Fails to Meet Endpoints

News for Teva Pharmaceutical Stock (TEVA)